arrow
A

Annalisa Capuano

department of experimental medicine
H指数:48
被引数:8,851

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adverse event reporting patterns of selective serotonin reuptake inhibitors (SSRIs): disproportionality analysis using the European spontaneous reporting system

选择性血清素再摄取抑制剂(SSRIs)的不良事件报告模式:基于欧洲自发报告系统的比例失衡分析

2026-09-190
OAAI
Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database

报告涉及利拉鲁肽、司美格鲁肽和替尔泊肽的自杀与自伤相关事件模式:欧洲药物警戒数据库的数据

2026-08-280
OA
Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database

评价胰高血糖素样肽-1受体激动剂的安全性特征:聚焦于甲状腺癌相关不良事件,使用欧洲药物警戒数据库

2026-05-280
OAAI
Cardioprotective mechanism of ω-3 fatty acid icosapent ethyl (IPE) in cardiomyocytes: role in high glucose and shear stress-induced mechano-transduction dysregulation

ω-3脂肪酸依柯萨彭特乙酯(IPE)在心肌细胞中的心脏保护机制:其在高糖和剪切应力诱导的力转导失调中的作用

2025-12-130
OAAI
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies

低丙种球蛋白血症和感染在用抗CD-20单克隆抗体治疗的多发性硬化患者中的发生情况:一项观察性研究的系统评价和荟萃分析

2025-10-240
PRE
METTL16-mediated inhibition of MXD4 promotes leukemia through activation of the MYC-MAX axis

Mettl16介导的MXD4抑制通过激活MYC-MAX轴促进白血病

2025-09-140
OAAI
Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data

利拉鲁肽和司美格鲁肽在体重管理中的真实世界安全性比较:来自欧洲药物警戒数据的见解

2025-07-250
OA
Clinical relevance and methodological approach for the assessment of drug–drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF)

癌症患者药物相互作用评估的临床相关性与方法学路径:意大利医学肿瘤学会(AIOM)和意大利药理学学会(SIF)的立场声明

2025-06-010
OA
“Aging and epigenetic implications in radiotherapy: The promise of BNCT”

“老龄化与放疗中的表观遗传学意义:硼中子俘获疗法(BNCT)的潜力”

2025-05-300
OA
Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database (APR, 10.1007/s40264-025-01535-8, 2025)

与JAK抑制剂相关的主要不良心血管事件:一项利用WHO全球个体病例安全数据库的不均衡性分析(APR, 10.1007/s40264-025-01535-8, 2025)

2025-04-220
OA
Oropharyngeal adverse drug reactions: knowledge, attitudes, and practice (KAP) among Italian healthcare professionals and students

口咽部药物不良反应:意大利医疗保健专业人员和学生的知识、态度和实践(KAP)

2025-04-110
OA
Treatment of sinusitis in children: an Italian intersociety consensus (SIPPS-SIP-SITIP-FIMP-SIAIP-SIMRI-SIM-FIMMG)
2025-03-260
OAAI